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ARTICLE
Analyses of gut microbiota and plasma bile acids
enable stratiﬁcation of patients for antidiabetic
treatment
Yanyun Gu 1, Xiaokai Wang2,3, Junhua Li 2,4, Yifei Zhang1, Huanzi Zhong 2,5, Ruixin Liu1, Dongya Zhang2,
Qiang Feng2, Xiaoyan Xie1, Jie Hong1, Huahui Ren2,4,6, Wei Liu7, Jing Ma7, Qing Su8, Hongmei Zhang8,
Jialin Yang9, Xiaoling Wang10, Xinjie Zhao10, Weiqiong Gu1, Yufang Bi1, Yongde Peng11, Xiaoqiang Xu2,3,
Huihua Xia2,4, Fang Li2,4,6, Xun Xu2, Huanming Yang2,12, Guowang Xu 10, Lise Madsen 2,3,13,
Karsten Kristiansen 2,5, Guang Ning1 & Weiqing Wang1
Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and
faecal bile acid (BA) composition, which may improve metabolic health. Here we show that
treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and
secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes
(T2D) patients, which may beneﬁcially affect metabolism. Acarbose increases the relative
abundances of Lactobacillus and Biﬁdobacterium in the gut microbiota and depletes Bacteroides,
thereby changing the relative abundance of microbial genes involved in BA metabolism.
Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to
treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a
high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement
in metabolic parameters after Acarbose treatment. Our work highlights the potential for
stratiﬁcation of T2D patients based on their gut microbiota prior to treatment.
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The importance of the intestinal microbiota in host healthand pathogenesis of several non-communicable diseasessuch as cancer, obesity and type 2 diabetes (T2D), and even
mental disorders is now recognised1, 2. Cross-sectional case-
control studies have revealed microbial dysbiosis in T2D
patients3, 4, possibly contributing to disease development.
Although solid proof of a causal link between gut microbial
dysbiosis and T2D is still missing, it has been reported that
therapeutic strategies such as bariatric surgery5, 6 and Metformin
treatment7–9 may confer metabolic beneﬁts including improved
glycaemic control through alteration of the gut microbiota. Fur-
thermore, recent studies have demonstrated that single bacterial
species associated with insulin resistance and obesity upon
transfer to normal speciﬁc pathogen-free (SPF) mice confer the
same phenotype to the recipient mice10, 11.
Host-gut microbiota interaction is central in bile acid (BA)
metabolism and signalling, and it is essential for the maintenance
of metabolic health12. Additionally, compared to healthy indivi-
duals, alterations in the levels and compositions of plasma BAs
have been observed in patients with diabetes or obesity13–15,
further highlighting a possible involvement of BA metabolism in
the pathogenesis of metabolic diseases. Finally, an animal study
suggests that BA signalling is required for mediating the ther-
apeutic effects of bariatric surgery16.
Acarbose, a pseudo-tetrasaccharide produced by Actinoplanes
species and an alpha-glycosidase inhibitor, is recommended in
China and other Asian countries as an alternative to Metformin
for ﬁrst line treatment of T2D17–19. Unlike classic oral anti-
diabetic drugs (OADs) such as thiazolidinediones or sulfonylur-
eas (SUs)20 with well-characterised molecular targets affecting
insulin resistance or secretion, Acarbose exerts its hypoglycaemic
effects by inhibiting the hydrolysis of complex carbohydrates on
the brush boarder of the upper intestinal epithelium thereby
reducing glucose absorption in this part of the intestine. This
further leads to an increased concentration of complex carbo-
hydrates in the lower part of the intestine21, potentially altering
microbial fermentation in the distal gut.
To elucidate how OADs may affect the gut microbiota, and
discriminate such changes from disease-dependent alterations,
intervention studies are needed on treatment-naive T2D patients
admitted to antidiabetic treatment. In a multicentre, randomised
and positively controlled clinical trial, where treatment-naive
T2D patients were assigned to treatment with one of two drugs
commonly used in China, Acarbose or the sulfonylurea Glipizide,
to achieve targeted glycaemic control, we compared the effects of
the two drugs on metabolic parameters, including plasma BAs,
and the intestinal microbiota. We identify drug-dependent
alterations in the microbiome and plasma BAs that correlate
with clinical measurements and outcomes, including body mass
index (BMI), blood glucose, glycated haemoglobin (HbA1c), lipid
proﬁles, insulin secretion and resistance status. Of interest,
treatment-naive T2D patients can be stratiﬁed into two groups
based on their individual baseline microbiomes. Patients har-
bouring a gut microbiota with a higher baseline abundance of
Bacteroides have lower levels of secondary BAs and exhibit more
beneﬁcial therapeutic responses to Acarbose treatment, including
reduced BMI, and improved insulin resistance status and lipid
proﬁle, suggesting that baseline metagenome signatures may be
used to stratify T2D patients prior to treatment.
Results
Baseline characteristics of patients and clinical outcomes. To
characterise the clinical effects of Acarbose and Glipizide, we
Table 1 Clinical parameters in the pre-treatment and post-treatment samples in the two treatment arms
Pre-treatment Post-treatment P value (Pre vs. Post)
Acarbose (n= 51) Glipizide (n= 43) P value Acarbose (n= 51) Glipizide (n= 43) P value Acarbose Glipizide
Demographic characteristics
Age (years) 53± 7 54± 7 0.497 NA NA NA
Gender (male/total) 34/51 24/43 0.387 NA NA NA
Body weight (kg) 74.7± 10.3 71. 5± 10.7 0.067 72.1± 10.1 70.6± 10.2 0.190 2.36E−07 0.138
BMI (kg/m2) 26.3± 3.2 26.0± 3.4 0.265 25.4± 3.2 25.7± 3.3 0.945 3.48E−07 0.113
WC (cm) 91.5± 8.5 90.7± 8.4 0.527 88.6± 7.3 89.5± 8.4 0.870 3.84E−04 0.144
WHR 0.92± 0.06 0.92± 0.05 0.485 0.90± 0.05 0.90± 0.06 0.779 0.005 0.019
Glycaemic characteristics
HbA1c (%) 7.5± 0.8 7.7± 0.9 0.541 6.4± 0.5 6.3± 0.7 0.508 1.45E−09 1.82E−08
FPG (mmol/L) 7.6± 1.4 7.9± 1.4 0.291 6.6± 0.9 6.7± 1.2 0.665 3.58E−07 2.48E−06
PPG (mmol/L) 14.3± 2.7 15.0± 2.8 0.164 9.2± 1.8 10.8± 2.8 0.002 5.30E−10 6.29E−10
AUC blood glucose (mmol/
L*min)
2241± 363 2381± 351 0.077 1507± 263 1804± 359 6.55E
−05
5.30E−10 6.98E−11
AUC Insulin (pmol/L*min) 5981± 3340 5460± 2507 0.697 3700± 1989 6618± 3536 1.62E
−06
2.40E−06 0.019
AUC C Peptide (ng/
mL*min)
528± 210 501± 154 0.978 389± 143 575± 161 1.94E
−07
1.94E−08 0.002
HOMA-IR (μIU *mmol) 3.7± 2.3 3.6± 2.1 0.868 2.6± 1.8 2.9± 2.1 0.638 0.002 0.050
Other clinical indices
SBP (mmHg) 127± 16 131± 18 0.431 121± 13 131± 19 0.128 0.022 0.043
DBP (mmHg) 82± 8 81± 10 0.675 75± 8 76± 9 0.703 2.94E−05 0.013
Triglycerides (mmol/L) 2.5± 2.1 2.1± 1.2 0.459 1.6± 1.2 1.7± 0.8 0.093 2.39E−05 0.382
Total cholesterol (mmol/L) 5.1± 1.2 4.9± 1.0 0.696 4.8± 1.2 4.8± 0.9 0.712 0.007 0.228
LDL cholesterol (mmol/L) 1.2± 0.4 1.2± 0.4 0.500 1.2± 0.3 1.3± 0.6 0.864 0.276 0.5355
HDL cholesterol (mmol/L) 3.1± 1.0 3.1± 0.8 0.492 3.0± 1.0 2.9± 0.8 0.514 0.484 0.0357
FLI 334± 554 237± 341 0.352 101± 147 1621± 271 0.400 1.92E−09 0.013
WC, waist circumference; WHR, waist–hip circumference ratio; HbA1c, glycated haemoglobin; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; AUC, area under the curve; HOMA-IR,
homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FLI, fatty liver index: FLI= (e0.953 × loge [TG] + 0.139 × BMI + 0.718 × loge[γGT] +
0.053 ×WC− 15.745)/(1 + e0.953× loge [TG] + 0.139 × BMI + 0.718 × loge [γGT] + 0.053 ×WC− 15.745) × 100. γGT, gamma-glutamyltransferase
Data are presented as mean± SD
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recruited patients from ﬁve centres in Shanghai, China. A total of
171 treatment-naive T2D patients were screened and based on
inclusion and exclusion criteria (Supplementary Table 1; regis-
tered in ClinicalTrials.gov. NCT01758471), 106 patients were
enrolled and 1:1 randomised into the two treatment arms (Sup-
plementary Methods). There was no difference between the two
arms in relation to gender, age and BMI (Table 1). Ninety-four of
the enrolled patients completed the study and were included in
the analyses, while 5 in the Acarbose group and 7 in the Glipizide
group were not included in the analysis (ﬂow chart shown in
Supplementary Fig. 1). The goal of the treatment was to achieve a
generally recommended targeted level of HbA1c below 7.0%22, 23
in both arms within 3 months, indicative of improved glycaemic
control. Faecal and plasma samples were collected at baseline and
after 3 months of treatment. There were no signiﬁcant differences
between anthropomorphic, metabolic, biochemical parameters
and HbA1c levels in the two groups at baseline (Wilcoxon rank-
sum test, P> 0.05, Table 1).
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Fig. 1 Major clinical outcomes in patients after 3 months of treatment with Acarbose or Glipizide. a Effect on glycated haemoglobin A1c (HbA1c), in the
Acarbose (brown) and Glipizide (white) arms, Wilcoxon rank-sum test. b Effects on fasting blood glucose concentration (FBG), postprandial blood glucose
concentration (PBG) in the Acarbose (brown) and Glipizide (white) treatment arms; paired Wilcoxon rank-sum test, *P< 0.01. c Effects on body weight
(BW) and body mass index (BMI) in the Acarbose (brown) and Glipizide (white) treatment arms. d Blood glucose excursion curve and e plasma insulin
release curve during the meal tests in the two treatment arms, paired Wilcoxon rank-sum test, *P< 0.01, + P< 0.05, pre-treatment vs. post-treatment with
Acarbose. f Effects on HOMA-IR, g Total cholesterol (TC) and triglycerides (TG) in the two treatment arms; paired Wilcoxon rank-sum test, *P< 0.01. n=
51 in Acarbose pre and Acarbose post-treatment, n= 43 in Glipizide pre and Glipizide post-treatment
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At the end of the 3-month treatment, the reductions in HbA1c
levels, and fasting blood glucose (FBG) and postprandial blood
glucose (PBG) levels were signiﬁcant in both groups (paired
Wilcoxon rank-sum test, P< 0.01 between baseline and treat-
ment, Table 1), and both arms reached the targeted level of
glycaemic control that did not differ signiﬁcantly (Wilcoxon
a b
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Fig. 2 Changes in bile acid composition in response to Acarbose treatment correlate with clinical outcomes. a Plasma levels of bile acids (BAs) before and
after Acarbose and Glipizide treatments. Results are shown as boxes denoting the interquartile range between the ﬁrst and third quartiles. The line within
the boxes denotes the median, paired Wilcoxon rank-sum test, *P< 0.01, + P< 0.05: Post-treatment vs. Pre-treatment in the Acarbose arm, n= 49 in
Acarbose pre and Acarbose post-treatment, n= 43 in Glipizide pre and Glipizide post-treatment. b Changes in the composition of BAs in the two treatment
arms; paired Wilcoxon rank-sum test, *P< 0.01, + P< 0.05: Post vs. Pre-treatment in the Acarbose arm. c Multivariate GEE analysis of the contribution of
BAs to the main clinical outcomes of Acarbose treatment. *P< 0.01, + P< 0.05, adjusted for BMI, sex and age. The colour key represents the regression
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glycoursodeoxycholic acid, TUDCA tauroursodeoxycholic acid, ABA sum of all measured plasma BAs, GCDCA glycochenodeoxycholic acid, TaurineBA
taurine-conjugated bile acids, GCA glycocholic acid
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rank-sum test, P> 0.05 between groups, Fig. 1a, b). However, the
reductions in body weight (BW) and BMI were more pronounced
in the Acarbose arm than in the Glipizide arm after 3 months of
treatment (Fig. 1c). The area under the curve (AUC) value of
insulin release was signiﬁcantly reduced after Acarbose treatment,
but increased as expected after Glipizide treatment during a
carbohydrate meal test containing 100 g ﬂour as described
previously24, (1029.9± 575.2 pmol/Lxmin vs. 637.1± 342.6
pmol/Lxmin, Acarbose pre vs. post-treatment, P= 2.41E−06;
940.2± 431.7 pmol/Lxmin vs.1139.6± 608.9 pmol/Lxmin, Glipi-
zide pre vs. post-treatment, P= 0.019; paired Wilcoxon rank-sum
test; Fig. 1d, e). In addition, patients receiving Acarbose but not
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Glipizide showed a signiﬁcant improvement in clinical para-
meters that are major risk factors for metabolic comorbidities and
cardiovascular complications of T2D, such as the homeostasis
model assessment of insulin resistance (HOMA-IR), total
cholesterol (TC), triglyceride (TG) and fatty liver index (FLI)25.
Of note, neither Acarbose nor Glipizide treatment increased, but
rather decreased plasma FGF19 levels, a key factor produced in
the intestine and shown to be of importance for metabolic
health26, indicating that improvement in HbA1c and FBG and
PBG levels was not dependent on FGF19, (Table 1; Fig. 1f, g, all
clinical parameters are given in Supplementary Table 2). Con-
sidering the known Acarbose-induced reduction of carbohydrate
absorption in the small intestine, we next investigated to what
extent Acarbose-induced changes in the gut microbiota might
contribute to the observed additional metabolic beneﬁts besides
the hypoglycaemic effect.
Changes in plasma BAs correlate with therapeutic beneﬁts.
Alterations in the composition of the BA pool in humans can
reﬂect intraluminal changes in the gut modulating gut-derived
signals that regulate host metabolism and alteration in plasma
BAs have been linked with metabolic disorders12. Thus, the level
of taurine-conjugated BAs (TaurineBA, the sum of all taurine-
conjugated BAs) is elevated in T2D15 and the ratio of 12-α OH to
non-12α OH BAs (12-α OH/non-12α OH BA ratio) in the total
BA pool has been linked to insulin resistance14. In our study, we
assayed 15 BA species using high-performance LC-MS/MS on
fasting plasma samples. At baseline, no differences in plasma BA
levels were observed between the treatment arms (Fig. 2a). After
treatment, plasma BA composition was substantially altered
solely in the Acarbose arm with the level of total BAs remaining
unchanged (Fig. 2b, Supplementary Table 3, paired Wilcoxon
rank-sum test, P< 0.05). Acarbose treatment decreased the levels
of plasma secondary BAs (SBAs), mainly conjugated deoxycholic
acids (DCAs). Due to the increased levels of cholic acid (CA) and
chenodeoxycholic acid (CDCA), we observed an increased overall
level of unconjugated primary BAs (PBAs). Further, the ratios of
PBAs to SBAs (PBA/SBA ratio) and unconjugated to conjugated
BAs (UnconBA/ConBA ratio) increased, whereas the levels of
TaurineBA and the 12-α OH/non-12α OH BA ratio decreased
after Acarbose treatment (Supplementary Table 3, paired Wil-
coxon rank-sum test, P< 0.05).
A multivariate correlation analysis based on the generalised
estimated equation (GEE) revealed that the Acarbose-induced
improvements of glycaemic control and other metabolic para-
meters were correlated with the changes in plasma BA
composition (Fig. 2c; Supplementary Table 4). The signiﬁcant
increases in the UnconBA/ConBA ratio and PBA/SBA ratio
correlated with improvements in HbA1c, BW, FLI, blood
pressure and lipid proﬁle (Fig. 2c, Supplementary Table 4). Via
deconjugation and the sequential dehydroxylation of PBAs to
produce SBAs, the gut microbiome is crucial for regulating BA
diversity27. The increased UnconBA/ConBA and PBA/SBA ratios
after Acarbose treatment indicated that Acarbose treatment
might alter two key steps of bacterial BA biotransformation.
Acarbose modulates the composition of the gut microbiota.
We next performed whole-metagenome sequencing on the 188-
paired faecal samples from the patients and generated 1.42 Tb of
high-quality sequencing data with an average of 7.7 Gb per
sample to investigate the differential responses of the gut
microbiome to the two types of antidiabetic treatment. Genes
were identiﬁed by aligning the reads to the 9.9 M integrated
reference catalogue of genes in the human gut microbiome28. On
average, 80.5% of the reads in each sample were mapped (Sup-
plementary Table 5). Metagenomic analyses demonstrated that
Acarbose treatment signiﬁcantly altered the relative abundances
of 141,382 microbial genes (paired Wilcoxon rank-sum test, q<
0.01), whereas no signiﬁcant changes in relative gene abundances
were observed following Glipizide treatment (Supplementary
Table 5). Rarefaction analyses revealed that the number of genes
in the microbiomes of patients in the Acarbose arm surprisingly
was signiﬁcantly decreased, whereas no changes were observed in
the Glipizide arm (Fig. 3a, b). In line with this observation, both
gene count and Shannon index decreased after Acarbose treat-
ment, but not after Glipizide treatment (Fig. 3c, d). Analysis of
species-level molecular operational taxonomic unit (mOTU)
proﬁles demonstrated that Acarbose led to signiﬁcant changes in
the relative abundances of 69 mOTUs (paired Wilcoxon rank-
sum test, q< 0.01; Fig. 3e; Supplementary Table 6); Glipizide
treatment did not affect the relative abundances of any mOTUs at
this signiﬁcance level. At baseline, there were no signiﬁcant dif-
ferences in relation to gene rarefaction, gene richness and gut
microbiome alpha diversity or taxonomic richness between the
two arms (Supplementary Fig. 2, Fig. 3c, d). Of note, despite of
the comparable hypoglycaemic effect of Glipizide and Acarbose
treatment, the gut microbiome alteration after Glipizide treat-
ment was small, suggesting that changes in blood glucose levels
were not a primary driver of the changes in the distal gut
microbiota. Unlike Glipizide that regulates the ATP-sensitive
potassium (KATP) channel activity of pancreatic β cells, Acarbose
impedes the hydrolysis and absorption of carbohydrates in the
small intestine, which in turn changes the abundances of sub-
strates for fermentation by the microbiota in the distal intestine,
thereby allowing saccharolytic Lactobacillus and Biﬁdobacterium
species to thrive and depleting the original distal gut-residing,
putrefactive species of Bacteroides, Alistipes and Clostridium
(Fig. 3e, paired Wilcoxon rank-sum test, q< 0.01).
Plasma BA changes, metabolic beneﬁts and gut microbiota. A
mutual interaction between host BAs and the gut microbiome
modulates the microbial biotransformation of BAs29. In the
untreated T2D patients at baseline, permutation multivariate
analysis of variance (PERMANOVA) analysis revealed that
plasma levels of the SBAs, ursodeoxycholic acid (UDCA), gly-
coursodeoxycholic acid (GUDCA), lithocholic acid (LCA) and
Fig. 3 Acarbose elicits stronger impact on the gut microbiota than Glipizide. Effects of Acarbose a and Glipizide b treatments on gene rarefaction, n= 51 in
Acarbose pre and Acarbose post-treatment, n= 43 in Glipizide pre-treatment and Glipizide post-treatment. All bar plots are shown as mean± S.D. The
number of genes in each group was calculated after 100 random samplings with replacement. The effects of treatment in both arms on gene richness c and
Shannon index d of the gut microbiome, n= 51 in Acarbose pre and Acarbose post-treatment, n= 43 in Glipizide pre and Glipizide post-treatment. e
mOTUs signiﬁcantly changed in abundance by Acarbose treatment (left panel), Benjamini–Hochberg q-value< 0.01, presented in box-plots to illustrate the
relative abundances of the different groups. The mOTUs are listed in the order of their relative abundances pre-treatment. mOTUs in red represent mOTUs
that decreased in abundance are after Acarbose treatment, whereas mOTUs that increased in abundance are given in green. The phylum colour code is
indicated to the left of the mOTU annotation. The same mOTUs did not change after Glipizide treatment (right panel of e). All plotted boxes are
interquartile ranges. Dark lines in the boxes indicate medians, the lowest and highest values within 1.5 times IQR from the ﬁrst and third quartiles. Outliers
are shown as circles beyond the whiskers. n= 51 in Acarbose, n= 43 in Glipizide, *Biﬁdobacterium catenulatum−Bpc: Biﬁdobacterium catenulatum-
Biﬁdobacterium pseudocatenulatum complex
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DCA correlated with changes in the composition of the gut
microbiota (Bray–Curtis distance, q< 0.01; Supplementary
Table 7). Interestingly, 58 out of the 69 mOTUs that exhibited
signiﬁcant changes in relative abundance in response to Acarbose
treatment also correlated with Acarbose-induced alterations in
plasma BA composition (GEE adjusted for age, sex and BMI, q<
0.05; Supplementary Data 1), pointing to a tight link between
Acarbose-dependent alterations of the gut microbiota and plasma
BA composition.
Many of the Acarbose-induced species have been classiﬁed and
used as probiotics, and the increase in the relative abundance
correlated with improvements in metabolic parameters (GEE
adjusted for age, sex and BMI, q< 0.05,; Supplementary Fig. 3).
Thus, Acarbose-induced increases in Lactobacillus gasseri and
Biﬁdobacterium longum correlated inversely with changes in BW
and HbA1c. These correlations are consistent with those observed
in mice treated with VSL3# (a probiotic supplement containing
strains of Lactobacillus, Biﬁdobacterium and Streptococcus)30 and
c
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with the effect of microbial overexpression of the gene encoding
bile salt hydrolase (Bsh) which also increased the UnconBA/
ConBA ratio in mice31. The reduced plasma DCA levels and
reduced BW gain after Acarbose treatment, correlated with the
reductions of Acarbose-depleted species, such as Bacteroides
plebeius, Bacteroides dorei/vulgatus and Clostridium bolteae.
These species harbour a multi-gene BA-inducible (bai) operon
encoding genes involved in 7-α/β dehydroxylation of BAs,
reported not to be present in probiotic bacteria27, 32.
Acarbose treatment alters gut bile acid composition. To explore
the possible impact of Acarbose on gut bacterial BA metabolism,
we performed functional annotations of genes using a manually
built reference library which includes 1011 annotated amino acid
sequences mapped to 16,102 genes implicated in bacterial BA
metabolism (Supplementary Table 8). The relative abundances of
genes encoding enzymes involved in bacterial BA modiﬁcation,
including BA deconjugation, BA transport, hydroxysteroid
dehydrogenation and 7α/β dehydroxylation were thus calculated
and compared between pre-treatment and post-treatment sam-
ples (Supplementary Table 8). The relative abundances of baiE
(encoding BA 7α-dehydratase, the rate-limiting enzyme for 7α-
dehydroxylation) and baiI (encoding BA 7β-dehydratase) were
signiﬁcantly decreased after Acarbose treatment, while the baiG
(encoding BA transporter) and genes encoding 7β-Hsdh (7β-
hsdh) showed signiﬁcant enrichment after Acarbose treatment
(paired Wilcoxon rank-sum test, P< 0.05; Fig. 4a; Supplementary
Table 9). None of these genes changed signiﬁcantly in relative
abundance after Glipizide treatment (paired Wilcoxon rank-sum
test, P> 0.05; Fig. 4a; Supplementary Table 9).
The taxa distributions of genes involved in BA metabolism
(Supplementary Data 2) in baseline samples revealed that B.
plebeius, B. vulgatus/dorei and B. dorei largely accounted for the
abundances of bsh, baiG and baiE. This suggested that these
Bacteroides species were mainly responsible for both BA
deconjugation and subsequent dehydroxylation in the distal gut
microbiota of treatment-naive T2D patients. After treatment, the
relative abundances of these genes were reduced due to the loss of
their dominant contributor species, or the dominant contributors
of some genes were replaced by other species. For example, the
dominant contributors of the genes encoding Bsh changed from
B. plebeius and B. vulgatus/dorei to B. longum, and Lactobacillus
amylovorus (Fig. 4b). The Biﬁdobacterium and Lactobacillus
genera have been reported to possess high Bsh activity, but are
lacking the bai genes32–34.
We investigated if the changes in the bacterial potential for BA
metabolism induced by Acarbose treatment were reﬂected in the
BA composition in the faecal samples. The total level of faecal
BAs was signiﬁcantly decreased after Acarbose treatment
(Supplementary Fig. 4a, b, Supplementary Table 10). Actually,
the faecal levels of the primary BAs, CA and CDCA, increased
following Acarbose treatment, but this was more than counter-
acted by the large decrease in the levels of the secondary BAs,
DCA and LCA (Supplementary Fig. 4a). Overall, these changes
resulted in an increased faecal PBA/SBA ratio in response to
Acarbose treatment (Supplementary Fig. 4d). The faecal
UnconBA/conBA ratio was unchanged (Supplementary Fig. 4c).
These changes mirrored the changed relative abundance of bai
genes with an unchanged relative abundance of bsh genes
following Acarbose treatment (illustrated in Fig. 4c), but do not
explain the signiﬁcant increase in the plasma UnconBA/ConBA
ratio after Acarbose treatment.
In addition to altering BA metabolism, bacterial functional
pathway analysis showed that Acarbose treatment also increased
the potential for glutamine synthesis, decreased the potential for
glycosaminoglycan degradation, and decreased the potential for
H2S and methane production (Supplementary Data 3), all
associated with host-gut barrier integrity and T2D risks3, 35–38.
Finally, both antidiabetic treatments reduced the abundances of
genes involved in type III secretion and LPS biosynthesis that are
linked to insulin resistance39, 40, suggesting the existence of
certain common routes in the response of the gut microbiome to
antidiabetic treatments despite the use of different medical agents.
Microbiota composition predicts the response to Acarbose.
Studies have suggested a stratiﬁcation of individuals by clustering
algorithms based on the genus composition of the intestinal
microbiota41, 42, but the concept of the existence of discrete
enterotypes has also been questioned, suggesting a continuous
distribution of enterotypes in an individual43. In our study, the
baseline microbiomes of patients could be clearly separated into
two enterotype-like clusters, one driven by Bacteroides (Cluster B)
and the other driven by Prevotella (Cluster P) shown by PCA
analysis (Supplementary Fig. 5a), network analysis (Supplemen-
tary Fig. 5b) and abundance box plot (Supplementary Fig. 5c). In
agreement with previous reports, anthropomorphic, metabolic
and biochemical parameters did not differ between patients from
the two clusters41 (Wilcoxon rank-sum test, P> 0.05, Supple-
mentary Table 11). However, already at baseline patients in
Cluster B had lower levels of LCA and DCA, and higher levels of
UDCA in the BA pool both in plasma and faeces. (Wilcoxon
rank-sum test, P< 0.05, Fig. 5a; Supplementary Tables 12, 13).
Patients in Cluster B also exhibited a higher plasma PBA/SBA
ratio and lower 12-α OH/non-12α OH BA ratio compared to
Fig. 4 Acarbose treatment affects the potential for secondary bile acid metabolism. a Comparison of the relative abundances of genes encoding enzymes
involved in SBA metabolism exhibiting signiﬁcant alterations in abundance after Acarbose treatment, but not after Glipizide treatment; Plotted boxes are
interquartile ranges. Dark lines in the boxes indicate medians, the lowest and highest values within 1.5 times IQR from the ﬁrst and third quartiles, paired
Wilcoxon rank-sum test, *p< 0.01, +p< 0.05. n= 51 in Acarbose pre and Acarbose post-treatment, n= 43 in Glipizide pre and Glipizide post-treatment.
baiG, baiI and baiE, bile acid-inducible (bai) gene G, I and E; hsdh, gene encoding hydroxysteroid dehydrogenase, bsh, gene encoding bile salt hydrolase. b
Cumulative relative abundances of genes encoding Bsh (EC.3.5.1.24) listed according to the contribution by annotated bacterial species pre-Acarbose and
post-Acarbose treatment. The x-axis represents the cumulative relative abundances of genes encoding Bsh. Only species where the genes encoding Bsh
constituted more than 0.5% of the total abundance of these genes, and where we observed a signiﬁcant difference in relative abundances of these genes in
response to Acarbose treatment, are included, q< 0.05, paired Wilcoxon rank-sum test. c Schematics of the bacterial BA biotransformation pathways,
including deconjugation and multiple steps of 7α/β-dehydroxylation. Faecal BAs and BA-metabolising enzymes encoded by genes enriched after Acarbose
treatment are marked in green, those depleted after Acarbose treatment are marked in red; those that did not change in abundance by treatment are
marked in grey. *indicates the rate-limiting enzyme of 7α-dehydroxylation. Bsh, bile acid hydrolase; Bai G/B/A/I/H/CD/E/F, enzymes encoded by the bai
operon. GCA glycocholic acid, TCA taurocholic acid, GCDCA glycochenodeoxycholic acid, TCDCA taurochenodeoxycholic acid, CA cholic acid, CDCA
chenodeoxycholic acid, UDCA ursodeoxycholic acid, DCA deoxycholic acid, LCA lithocholic acid. Boxes framed by dashed lines represent enzymes where
the annotation is ambiguous because of inconsistent functional annotation using BlastP based on the Uniprot database vs. BlastKOALA based on the KEGG
database. (See Supplementary Methods, Functional annotation of genes involved in BA synthesis based on BLASTP and BlastKOALA for further details)
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patients in Cluster P (Wilcoxon rank-sum test, P< 0.05, Fig. 5a;
Supplementary Table 12). Further, patients in Cluster B exhibited
signiﬁcantly decreased relative abundance of baiG, but increased
relative abundances of bsh, and 7β-hsdh, whereas baiE and baiI
exhibited similar relative abundances in both clusters (Wilcoxon
rank-sum test, P< 0.05, Supplementary Table 14). Interestingly,
the clinical effects of Acarbose were more pronounced in patients
belonging to Cluster B than in patients belonging to Cluster P.
Despite a similar improvement in HbA1c levels by Acarbose
treatment, patients in Cluster B exhibited signiﬁcantly greater
improvements in G0 (FBG), insulin, C peptide levels and,
therefore, HOMA-IR over baseline levels than patients in Cluster
P (Fig. 5b; Supplementary Fig. 6a; Wilcoxon rank-sum test, P<
0.05, see also Supplementary Table 15 for all results). We
observed the same tendency in the Glipizide arm. The compo-
sitions of the gut microbiome of patients in Cluster B changed
signiﬁcantly with depletion of the dominant Bacteroides genus
and the increase of the Biﬁdobacterium genus after treatment,
whereas fewer changes were observed in the gut microbiomes of
patients belonging to Cluster P (Supplementary Fig. 6b; Wilcoxon
rank-sum test, P< 0.01). Further, Acarbose treatment led to a
decreased abundance of baiE and an increased abundance of 7β-
hsdh and baiG, exclusively in patients in Cluster B (Supplemen-
tary Fig. 6c). Together, these results suggest that some of the
therapeutic effects of Acarbose-induced modulation of the gut
microbiota are related to bacterial BA metabolism and, therefore,
BA signalling.
Discussion
This study compared the effects of two antidiabetic drugs on the
gut microbiota, plasma BAs and their relations with clinical
outcomes in a clinical trial-based cohort. A key ﬁnding of this
study is that the baseline composition of the gut microbiota may
be used for stratiﬁcation of patients prior to initiation of
treatment.
The signiﬁcant reductions in BW with targeted glycaemic
control after Acarbose treatment is in line with earlier studies44,
45. Further, we demonstrate that patients receiving Acarbose, but
not Glipizide showed a signiﬁcant improvement in the HOMA-
IR, lipid proﬁle and FLI. The results of plasma BA proﬁling and
the multiple correlations between changes of plasma BAs and
clinical parameters, including BW, HOMA-IR, lipid proﬁle and
FLI, indicate that the modulation of BA signalling may contribute
to the unique metabolic effects of Acarbose. The increased levels
of plasma CDCA and an increased UnconBA/ConBA ratio
induced by Acarbose may enhance in vivo FXR activity46 and
change the faecal BA composition, resulting in decreased intest-
inal lipid absorption and reduced hyperglycaemia47, 48. Interest-
ingly, plasma UnconBA/ConBA and PBA/SBA ratios were also
shown to increase after biliopancreatic diversion surgery13, which
in a 2-year follow-up study was reported to result in superior
improvements in hyperglycaemia and dyslipidaemia compared to
the Roux-en-Y bypass and conventional medical therapy49. The
notion that similar changes in BA composition and correlations
between metabolic traits and plasma BAs after both Acarbose
treatment and gut reconstruction surgeries, despite differences in
populations, sample size and follow-up time, points to the
importance of BA signalling in metabolic control in T2D
treatments.
Acarbose treatment led to increased abundances of species
possessing high Bsh activity, mainly B. longum, L. gasseri and
reduced abundance of the SBA producers, B. plebeius, B. vulgatus/
dorei and C. bolteae. Further functional analysis showed
decreased abundances of genes encoding the rate limited enzyme
for 7α/β dehydroxylation and a switch in the main contributors of
BA deconjugation enzymes from Bacteroides spp. to Lactobacillus
and Biﬁdobacterium spp., which barely contain bai genes. Thus,
the metagenomics analyses indicated lower capacity for BA 7α/β
dehydroxylation after Acarbose treatment, which is in keeping
with the observed increased plasma and faecal PBA/SBA ratios.
Interestingly, the increased ratio of UnconBA/ConBA was
observed in plasma, but not in faecal samples, and the abun-
dances of bacterial bsh genes did not change either. This would
argue against an increased potential of bacterial deconjugation in
response to Acarbose treatment, even in patients harbouring
higher abundancies of species such as B. longum and L. gasseri
which have been reported to possess high Bsh activity. However,
deconjugation occurs in the upper part of intestine and most of
unconjugated PBAs are reabsorbed in the ileum, and thus, to
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Fig. 5 Plasma bile acid composition and therapeutic responses to Acarbose treatment differ in patients with a different baseline microbiota composition. a
Plasma composition of bile acids in patients belonging to baseline enterotype-like clusters driven by Bacteroides (Cluster B) or Prevotella (Cluster P). Plasma
levels of DCA, LCA, GDCA, GLCA and UDCA differed signiﬁcantly between Cluster B and Cluster P at the baseline; plotted boxes are interquartile ranges.
Dark lines in the boxes indicate medians, the lowest and highest values within 1.5 times IQR from the ﬁrst and third quartiles, Wilcoxon rank-sum test, *P<
0.01, +P< 0.05. DCA deoxycholic acid, LCA lithocholic acid, GDCA glycodeoxycholic acid, GLCA glycolithocholic acid, UDCA ursodeoxycholic acid. b
Percentage changes over baseline levels of fasting blood glucose (G0), insulin (Ins0), C peptide (CP0) and HOMA-IR differed signiﬁcantly between Cluster
B and Cluster P after Acarbose treatment; paired Wilcoxon rank-sum test, *P< 0.01, +P< 0.05. Cluster B, n= 36, Cluster P, n= 15 in Acarbose arm, bar
plot is shown as mean± S.D.
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what extent the UnconBA/ConBA ratio in the faecal sample
represents a valid proxy for in vivo bacterial deconjugation
capacity needs to be further investigated. It is possible that the
signiﬁcantly reduced level of FGF19, which conveys the main
inhibitory intestinal BA signal for hepatic BA neo-synthesis30, 50,
51 or an altered intestinal BA reabsorption after Acarbose treat-
ment may contribute to the discrepancy between the UnconBA/
ConBA ratios in plasma and faecal samples. However, taken
together our results clearly point to the importance of Acarbose-
induced changes in the composition of the gut microbiome and
the observed alterations in BA proﬁles.
With the increased attention on the metabolic signiﬁcance of
BA signalling, the discovery of an Acarbose-gut microbiota-BA
axis may aid the identiﬁcation of novel modalities for therapeutics
intervention targeting the gut microbiome or plasma BAs. The
implication of gut microbiota-plasma BA axis underlying ther-
apeutic effects of Acarbose is further supported by the ﬁnding of
more pronounced changes in plasma BA composition and clinical
beneﬁts of Acarbose treatment in patients where the baseline
microbiomes belonged to an enterotype-like cluster driven by
Bacteroides (Cluster B) vs. those belonging to an enterotype-like
cluster driven by Prevotella (Cluster P).
In conclusion, our results suggest that the differential ther-
apeutic responses are related to distinct abilities of the microbial
communities in the two microbiome clusters to metabolise BAs,
and, more importantly, our ﬁndings demonstrate that stratiﬁca-
tion of patients according to baseline gut microbiota composition
may provide a tool for selecting medication strategy and pre-
dicting antidiabetic metabolic beneﬁts.
Methods
Trial design. This study was a randomised, open-label, two-arm, multicentre
clinical trial. Five centres participated in this study: Ruijin Hospital, Renji Hospital,
Xinhua Hospital, all afﬁliated to Shanghai Jiaotong University Medical School,
Shanghai General Hospital afﬁliated to Shanghai Jiaotong University and Central
Hospital of Minhang District afﬁliated to Fudan University Medical School. The
study was approved by the Institutional Review Board at each hospital and is
registered at ClinicalTrials.gov (NCT01758471). Written informed consent was
obtained from each patient. The study was conducted in accordance with the
principles of the Declaration of Helsinki.
Randomisation and treatment. After administration of a glucose tolerance test
and evaluation of other baseline characteristics, eligible patients were diagnosed
according to the 1999 World Health Organization criteria with fasting plasma
glucose ≥7 mmol/L and/or an oral glucose tolerance test (OGTT) 2 h≥11.1 mmol/
L52 and randomly assigned to receive either Acarbose or Glipizide treatment,
(detailed screening and recruitment procedures are provided in the Supplementary
Methods, Screening, recruitment, dietary information and follow-up). The ran-
domisation codes were generated with SAS (version 9.2; SAS Institute, Cary, NC)
by a biostatistician who did not participate in the enrolment of patients. A formal
power analysis was not performed to calculate sample size. The sample size for this
interventional study was selected based on previous studies of changes in the
composition of the gut microbiota in T2D3 and other diseases that compared the
effects of different therapeutic strategies on intestinal microbiota53, 54, considering
potential withdraw and loss to follow-up.
Patients were instructed to visit every month for the measurement of fasting
and postprandial glucose levels. The drug dosage was modiﬁed according to the
glycaemic control at each visit (targeted FBG< 7.0 mmol/L and PBG< 10.0 mmol/
L). After 3 months of treatment, all patients were again conﬁned in the hospital as
for the run-in period, served the same meals for lunch and dinner as during the
ﬁrst visit, fasted overnight and given an oral glucose load the next morning. Blood
samples, faeces and urine were collected as described above (more details are
provided in the Supplementary Methods, Screening, recruitment, dietary
information and follow-up).
Sample preparation. One day before the ﬁrst visit, the enrolled patients were
conﬁned in the hospital and served the same meals for lunch and dinner. Faeces
and urine were collected in dispensable sterile containers. Samples were kept on dry
ice before being stored at −80°C. Patients were fasted overnight. At 0800 hours, the
patients ingested a carbohydrate meal containing 100 g of ﬂour as an oral glucose
load24. Blood samples were taken before and 30 min, 60 min, 120 min and 180 min
after the meal test. The blood samples were immediately supplemented with a
dipeptidyl peptidase-4 inhibitor (for GLP-1 measurement; Millipore, Billerica, MA,
USA), the serine protease inhibitor Pefabloc SC (AEBSF for active ghrelin mea-
surement; Roche, Basel, Switzerland) and a protease inhibitor cocktail (Millipore,
Billerica, MA, USA). Serum and plasma samples were prepared and kept on dry ice
before storage at −80°C.
Laboratory assays. Plasma levels of cytokines and hormones were measured using
standard kits (Millipore, Billerica, MA, USA) on a Luminex FlexM3D™ system with
xMAP Luminex technology. HbA1c was measured by high-performance liquid
chromatography using the VARIANT II HbA1C Testing System (Bio-Rad
Laboratories, Hercules, CA, USA). Plasma BAs were assayed by LC-MS/MS with
multiple reaction monitoring, using a 1290 Inﬁnity LC system (Agilent, Santa
Clara, CA, USA) coupled with 6460 A Triple Quadrupole mass spectrometry
(Agilent, Santa Clara, CA, USA), and the Waters Acquity UPLC system (Waters,
Milford, MA) coupled to a Triple Quad™ 5500 tandem mass spectrometer (AB
Sciex, Framingham, MA) was used in analysis of BAs in faecal samples. Chro-
matographic separation was performed on a 100 mm × 2.1 mm ACQUITY UPLC
C8 column for plasma samples and UPLC BEH C18 column for faecal samples
with 1.7 µm particle size (Waters, Milford, MA, USA). Sample preparations for BA
assay were performed as described previouly55.
Glucose and biochemical parameters for assaying hepatic function, renal
function, blood electrolytes and lipid proﬁles were determined using the AU5800
Clinical Chemistry System (Beckman Coulter, Brea, CA, USA).
Metagenomic sequencing and annotation. DNA was extracted from stool
samples as described previously3. We constructed one DNA paired-end (PE)
library with an insert size of 350 base pairs (bp) for each sample following the
manufacturer’s instructions (Illumina, San Diego, California, USA). All samples
were sequenced using the 100-bp PE strategy on Illumina HiSeq 2500. The
sequencing data are available at the European Nucleotide Archive with code
PRJEB12124. Adaptor contamination and low-quality reads were discarded from
the raw reads, and the remaining reads were ﬁltered to eliminate human host DNA
based on the human genome reference (hg18). The gene proﬁles were generated by
aligning high-quality sequencing reads to the reference gene catalogue as previously
described28. Similarly, the relative abundance proﬁles of genera, species and Kyoto
Encyclopaedia of Genes and Genomes (KEGG) orthologous groups (KOs) were
determined from the gene abundances of mOTUs were obtained using mOTU
proﬁling software56.
Analysis of richness and biodiversity. Rarefaction and α-diversity analysis
(within-sample diversity) were performed as described by Li et al27. The gene
counts in each faecal sample were determined as previously reported57. Rarefaction
analysis was performed to assess gene richness in the T2D patients before and after
the patients had been treated with drugs for 3 months. For the rarefaction analysis,
we performed random sampling 100 times in the cohort with replacement and
estimated the total number of genes that could be identiﬁed from these samples
using the Chao2 richness estimator. To minimise erroneous identiﬁcation, only the
genes with ≥1 pair of mapped reads were considered to be present in a sample.
Correlations between microbial genes and plasma BA species. The interactions
between gene abundance proﬁles and each of the 15 plasma BA species were
assessed by PERMANOVA with the Bray–Curtis distance. The number of per-
mutations was 9999 (performed using the vegan package in R 3.3.1).
Multivariate regression analysis. A GEE analysis (corrected for age, sex and
BMI) was performed to explore Acarbose-induced longitudinal associations
between changes in (1) BA species and clinical parameters, (2) BA species and the
mOTUs signiﬁcantly altered in relative abundance by Acarbose and (3) the
mOTUs signiﬁcantly altered in relative abundance by Acarbose and clinical
parameters. The P value of each regression coefﬁcient was calculated, and an
adjusted P value of <0.05 was considered signiﬁcant (performed using the gee
package in R 3.3.1).
All regression analyses between BW and other traits were conducted after
adjustment for age and sex, but not BMI.
KEGG enrichment analysis. Differentially enriched KO modules were identiﬁed
according to their reporter scores from the Z-scores of individual KOs as described
previously58. An absolute value of reporter score of 1.95 or higher was used as the
detection threshold for signiﬁcance.
Clustering of microbial community types. Samples were clustered based on the
genus proﬁles. Two enterotype-like clusters were identiﬁed in our samples using
the method described previously36. In this study, samples were clustered using
Jensen–Shannon distance and presented by a PCA (Principal Component Analysis)
graph implemented in the 'ade4' package in R.
Identiﬁcation of microbial genes involved in BA biotransformation. We
retrieved 11 enzymes involved in microbial BA metabolism from UniProt (Uni-
versal Protein Resource) protein database. After removing redundant sequences
with greater than 90% identity, a total of 1011 amino acid sequences were obtained
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and used as the reference database for the blast search. Detailed information,
including the Enzyme Commission number (EC number), KO number, protein
name and search keywords are provided in Supplementary Table 8.
The 1011 amino acid sequences were then aligned with the predicted amino
acid sequences translated from the 9.9 M gene catalogue using NCBI-BLASTP
(E-value < 1E−5 and bit score> 60). In total, 16,102 genes potentially encoding
enzymes involved in BA metabolism were identiﬁed. Additionally, we assessed the
16,102 potential-hits against KEGG using BlastKOALA (KEGG Orthology And
Links Annotation) algorithm59 and compared the best hits with UniProt based
BLASTP results. Accordingly, only genes exhibiting highly consistent annotation
(bsh, baiE, baiG, baiI and 7β-hsdh) have been included in the analyses (for more
detailed description and discussion, see Supplementary Methods, Functional
annotation of genes involved in BA synthesis based on BLASTP and BlastKOALA,
and Supplementary Data 4–7).
To identify dominant species harbouring BA-metabolising enzymes, we
summed the total relative abundances of genes with a potential to encode enzymes
involved in BA metabolism and calculated the cumulative relative abundances of
these genes according to the contribution of each species harbouring the genes:
(relative gene X abundance in one species/total relative abundances of gene X) ×
100%.
If the species contributed more than 0.5% of the total pool, this species was
considered as a dominant contributor.
Statistical analyses. Paired Wilcoxon rank-sum tests were conducted to detect
differences in clinical parameters, BAs, genes and mOTUs pre-treatment and post-
treatment. P values were adjusted by the Benjamini–Hochberg correction. A P
value or an adjusted P value of less than 0.05 was considered signiﬁcant.
Data availability. Metagenomic sequencing data for all samples have been
deposited in the European Bioinformatics Institute (EBI) database under accession
code PRJEB12124. All other data are available upon request.
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